3% compared with the previous year, but earnings declined 14.1% to $0.55 per share. Analysts remain wary of investing in Abbott, due to widespread uncertainty about the direction of U.S. health reform and generic competition. Its most successful drug Continue Reading...
Their sole purpose is conducting medical and science research. These include providing funding as well as facilities to: individual scientists, universities and in some cases private corporations. If Abbott Labs can form some kind of partnership wit Continue Reading...
pag). Some business will continue as usual, of course: Abbott's nutrition division, based in Columbus, Ohio and employing approximately 2,000 people, announced that the nutrition unit will "fall under the umbrella of a new medical products company th Continue Reading...
It must also begin to develop a test population of genetically suitable subjects. However, Abbott also faces a potential weakness within the organization in terms of its distribution of medications. Through exclusive sourcing agreements Abbott has Continue Reading...
Abbott must expand its pharmaceutical research endeavors to ensure that it is consistently generating new drugs that are superior in quality to its competitors. Good research requires constant infusions of new talent and knowledge into the company. Continue Reading...
